Work as Formulation Development Scientific Leader at Apotex
Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world. We are the 7th largest generic pharmaceutical company globally with more than 12,000 employees and estimated sales of approximately $3 billion. Our fully integrated operation is comprised of four lines of business: Global Generics; Apobiologix; Global Active Pharmaceutical Ingredients (API); and ApoPharma (Innovative Products). With our worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. We produce 300 medicines in 4,000 dosages and formats that are exported to 115 countries. Apotex will spend $2 billion over the next 10 years on research and development.
Post : Formulation Development Scientific Leader
Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $13 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.
The Indian National Science Academy (INSA) was established in January 1935 with the object of promoting science in India and harnessing scientific knowledge for the cause of humanity and national welfare. The foundation of the Academy, earlier known as the National Institute of Sciences of India (NISI), was the outcome of joint endeavours of several organizations and individuals and the Indian Science Congress Association (ISCA) playing a leading role in this regard.
The Indian Institute of Technology Kanpur was established in the year 1960. The Parliament of India passed the ‘Institutes of Technology Act 1961’ declaring all the IITs as “Institutions of National Importance”. The Parliamentary Act has given absolute autonomy to the IITs. When the foundation stone of the IIT system was laid, it was perceived that taking help from the industrially advanced western countries might be lot more effective in achieving the status of a world class technical institute. Hence, IIT Kanpur had a massive collaboration with USA through a specially created programme- KIAP (Kanpur Indo American Programme).
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.
The Mumbai University Institute of Chemical Technology, known earlier as UDCT is the most outstanding Institute of the University of Mumbai. This prestigious institute is a jewel in the crown of the University of Mumbai. It was founded on 4th August 1934 and was recently awarded the status of the Institute on 26th January 2002 and renamed MUICT. It enjoys a unique and prominent place amongst the premier institutes that are engaged in education, training and research in the field of Chemical Engineering, Chemical Technology and Pharmacy in India. Located in central Mumbai over a lush green campus of 16 acres, the MUICT has a built-up area of 33000 m2 including classrooms, laboratories and hostels.
Covance, a $15 billion Fortune 500 company, with operations in over 97 countries, has led the way in improving patient outcomes through visionary data sciences over the last five decades. We have supported 100% of the top 50 drugs in the market and all the oncology medicines approved in 2016. Our team of over 57,000 across the globe is committed to advancing healthcare and bringing new medicines to market sooner. Our unique perspectives, built from decades of scientific expertise and precision delivery, help our clients identify new approaches and anticipate tomorrow’s challenges as they evolve. Driven by a passion for excellence and a relentless commitment to quality, we unlock opportunities that advance innovation and deliver the promise of a healthier world. Together, with our large pharmaceutical and emerging biotech clients, Covance transforms today's health care challenges into tomorrow's solutions.
Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.
